Pharmafile Logo

Competition from within

August 25, 2015 | emerging markets 

Published in eyeforpharma July 29 by Rachel Howard

To what extent can Big Pharma expect to face an increasing challenge from globalizing pharmaceutical companies based in emerging markets?

If we take a look at the top 50 pharmaceutical companies of 2013, they are mainly headquartered in North America (18), the EU (18) or Japan (9). Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy – which have since merged – the only representation from the ‘BRIC’ markets (Brazil, Russia, India and China). In ten years’ time, will more ‘home-grown’ emerging market companies feature on this list?

In this article, I will explore and compare the directions the domestic pharmaceutical industries of South Korea, China and Brazil have taken in recent years, and consider what threat, if any, each poses to established pharmaceutical companies on a global scale.

Read the full article here http://www.researchpartnership.com/news/2015/07/competition-from-within/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Research Partnership launches Access CGT

Research Partnership’s specialist market access team have launched Access CGT, a new syndicated access and policy tracker providing surveillance of the cell and gene therapy space.Read more

New syndicated reports now available

Living with CD, PsO, IPF & PF-ILD 2023

Article: Could combating stigma increase the uptake of PrEP and finally end the HIV epidemic?

In this article we explore what more could be done by the pharmaceutical industry to help prevent the spread of HIV infection worldwide.

Webcast: China Update 2023: How will recent developments impact your brand’s success?

Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

Webcast: How to improve the patient journey through an effective engagement and activation strategy

Watch part two in a series, Evolving Patient Journeys, in which experts from across Inizio explore why, despite best intentions, patient engagement solutions can fall short of expectations.

Webcast: Evolving Patient Journeys – How to generate deeper insights in a changing healthcare landscape

Watch part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years.

Infographic: Living with: The journey from the patient’s perspective

View our re-vamped interactive infographic to unlock key insights from various Living With reports

Case study: How we iteratively tested and refined payer value messages

Find out how we helped our client to enrich their understanding of the value message trade-off choices and preferences made by payers

Video: Strategic engagement case study

Supporting the launch of a global vaccine with a programme of market research and strategic insights

Webcast: The virtual patient: How to use AI-powered conjoint to understand complex treatment decisions

Watch to find out how a combination of virtual patients and artificial intelligence can help you to better understand physicians’ decision making processes.